Alcidion accorded preferred provider status in the UK
Shares in Alcidion Group Ltd (ASX:ALC) traded nearly 10% higher on Tuesday morning after the company announced that it had been selected in the UK as the preferred provider for Dartford and Gravesham NHS Trust’s Electronic Prescription Medications Administration System.
Importantly, the award of preferred provider status resulted from a competitive tender process.
Upon final contract, Alcidion will deploy Better by Marand’s OPENeP platform, an electronic medication management system that is designed to prevent adverse medication related events.
In April 2019, Alcidion was appointed as a reseller partner by Better by Marand for the UK, Australia and New Zealand.
Alcidion managing director Kate Quirke noted that this was an endorsement of the group’s broader capabilities in saying, “We are delighted to extend our existing relationship with the Dartford and Gravesham NHS Trust.
Potential for further opportunities
‘’The selection of Alcidion demonstrates the breadth of our capabilities and our value as the Trust’s strategic partner to support its goal of being Paperless at the Point of Care by 2020.
“This is the first major tender for which Alcidion has been selected to supply the OPENeP platform.’’
The award of preferred provider status demonstrates the power of Alcidion’s expanded portfolio of complementary products and solutions that sit alongside Miya and Patientrack, enabling the group to offer a truly best-of-breed integrated solution that covers a wide range of clinical needs including next generation medications management.
This is subject to approval of the business case by the Trust Board and successful negotiation and final approval of a contract, which is expected in late 2019.
It should be noted that Alcidion does not normally announce the award of preferred provider status, however this information is considered material and likely to be shared beyond the Trust and Alcidion and hence has been released ahead of a final contract being signed.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.